Climb Bio, Inc. Common Stock
Symbol: CLYM (NASDAQ)
2.03
▲ (1.76%) 0.035
Company Description:
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.
Key Stats
- Today's Open: $2.03
- Today's High: $2.08
- Today's Low: $1.961
- Today's Volume: 495.56K
- Yesterday Close: $1.99
- Yesterday High: $2.1592
- Yesterday Low: $1.9801
- Yesterday Volume: 338.03K
- Last Min Volume: 2
- Last Min High: $2.025
- Last Min Low: $2.025
- Last Min VWAP: $2.025
Company Profile
- Name: Climb Bio, Inc. Common Stock
- Website: https://www.climbbio.com
- Listed Date: 2021-08-10
- Location: WELLESLEY HILLS, MA
- Market Status: Active
- CIK Number: 0001768446
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $134.85M
- Round Lot: 100
- Outstanding Shares: 67.76M
- Asset Type: CS
RECENT FILINGS FOR CLYM
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-10-17 | 8-K | View |
| 2025-10-16 | SCHEDULE 13D/A | View |
| 2025-10-07 | SCHEDULE 13D/A | View |
| 2025-10-01 | 4 | View |
| 2025-10-01 | 3 | View |
| 2025-10-01 | 8-K | View |
| 2025-09-29 | 8-K | View |
| 2025-09-18 | SCHEDULE 13G | View |
| 2025-08-12 | 10-Q | View |
| 2025-08-12 | 8-K | View |
| 2025-08-11 | 4 | View |
| 2025-07-01 | 4 | View |
| 2025-07-01 | 4 | View |
| 2025-06-23 | 3 | View |
| 2025-06-20 | 4 | View |
| 2025-06-20 | 4 | View |
| 2025-06-20 | 3 | View |
| 2025-06-18 | 8-K | View |
| 2025-06-05 | 4 | View |
| 2025-06-05 | 4 | View |
Latest News on CLYM